ELN 2017 Recommendations Establish Genomic Risk Classification and MRD Framework for AML
This European LeukemiaNet consensus document updated the 2010 AML guidelines, incorporating advances in genomic profiling and measurable residual disease detection. It introduced a revised genetic risk classification, proposed MRD-based response categories, and defined criteria for disease progression. The recommendations became the global standard for AML diagnosis, risk stratification, and MRD-guided therapy decisions.
The original study
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
- Authors
- Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al.
- Journal
- Blood
- Type
- Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PMID
- 27895058
Original abstract
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.